I have a different perspective because IMU and CU6 have been among my best earners. So far, Alan has done very well at Clarity. I’m not seeing much similarity fundamentally with IMU and AT is solely focused on Clarity. His background looks great to me and he hasn’t put a foot wrong so far.
Scientific Background: Taylor holds a PhD in Medicine from the Garvan Institute of Medical Research and an undergraduate degree in Applied Science from the University of Sydney, where he was awarded the University Medal.
Investment Banking Experience: He has 15 years of experience in investment banking, with a focus on the life sciences sector, including capital raisings and mergers and acquisitions. He previously worked as an Executive Director at Inteq Limited, a boutique Australian investment bank.
Role at Clarity Pharmaceuticals: He joined Clarity as Executive Chairman in 2013 when the company was in its early stages. He has been crucial in its growth, including leading the company through its IPO on the ASX.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)